Advertisement

Arterielle Hypertonie - Aktuelle Probleme und Aufgaben

  • A. Distler
Conference paper

Zusammenfassung

Unter den derzeit aktuellen Problemen auf dem Gebiet der Behandlung der Hypertonie möchte ich auf folgende Fragen näher eingehen:
  • Soll die sog. milde Hypertonie behandelt werden?

  • Welche Medikamente sind für die Behandlung der milden Hypertonie geeignet?

  • Besitzen β-Rezeptorenblocker eine „kardioprotektive“ Wirkung?

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Helgeland A (1980) Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Amer J Med 69: 725PubMedCrossRefGoogle Scholar
  2. 2.
    Management Committee The Australian therapeutic trial in mild hypertension. Lancet 1980/1: 1261Google Scholar
  3. 3.
    Medical Research Council Working Party (1985) MRC trial of treatment of mild hypertension: principal results. Brit Med J 291: 97CrossRefGoogle Scholar
  4. 4.
    Society of Actuaries (1972) Build and Blood Pressure Study. Society of Actuaries, Chicago (1959)Google Scholar
  5. 5.
    Dawber TR, Kannel WB (1972) Current status of coronary prevention. Prev Med 1: 499PubMedCrossRefGoogle Scholar
  6. 6.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. J Amer med Ass 202: 1028Google Scholar
  7. 7.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents (1970) Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. J Amer med Ass 213: 1143Google Scholar
  8. 8.
    Management Committee of the Australian Therapeutic Trial (1982) Untreated mild hypertension. Lancet 1: 185Google Scholar
  9. 9.
    Freis ED (1982) Should mild hypertension be treated? New Engl. J Med 307: 306PubMedCrossRefGoogle Scholar
  10. 10.
    Smith WM (1977) Treatment of mild hypertension. Results of a ten-year intervention trial. US- Public Health Service Hospital Cooperative Study Group. Circ. Res., 40 (Suppl I), 98Google Scholar
  11. 11.
    Hypertension Detection and Follow-up Programm Cooperative Group (1979) Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. J Amer med Ass 242: 2562Google Scholar
  12. 12.
    Hypertension Detection and Follow-up Program Cooperative Group (1982) The effect of treat-ment on mortality in „mild“ hypertension. New Engl J Med 307: 976CrossRefGoogle Scholar
  13. 13.
    Hypertension Detection and Follow-up Programm Cooperative Group (1982) Five-year findings of the hypertension detection and follow-up programm. III. Reduction in stroke incidence among persons with high blood pressure. J Amer med Ass 247: 633CrossRefGoogle Scholar
  14. 14.
    Multiple Risk Factor Intervention Trial Research Group (1982) Multiple Risk Factor Interven-tion Trial. Risk factor changes and mortality results. J Amer med Ass 248: 1465Google Scholar
  15. 15.
    Guidelines for the treatment of mild hypertension (1983) memorandum from a WHO/ISH meeting. Lancet 1: 457Google Scholar
  16. 16.
    Wilkinson PR, Hesp R, Issler H, Raftery EB (1975) Total-body and serum potassium during prolonged thiazide therapy for essential hypertension. Lancet I: 759CrossRefGoogle Scholar
  17. 17.
    Heimsoth V und Hartmann F (1965) Untersuchungen zur Störung des Harnsäurestoffwechsels nach Saluretica-Verabreichung. Dtsch Med Wschr 43: 1905CrossRefGoogle Scholar
  18. 18.
    Distler A, Keim JH, Philipp Th, Walter U (1975) Blutdrucksenkende Wirkung von Spironolac-tone und von Butizid bei Patienten mit essentieller Hypertonie und niedrigem sowie mit norma-lem Plasmarenin. Therapiewoche 25: 3039Google Scholar
  19. 19.
    Jahnecke J (1973) Diabetogene Nebenwirkungen der Pharmakotherapie. Med Klin 68: 1046PubMedGoogle Scholar
  20. 20.
    Lewis PJ, Kohner EM, Petrie A, Dollery CT (1976) Deterioration of glucose tolerance in hyper-tensive patients on prolonged diuretic treatment. Lancet 1: 564PubMedCrossRefGoogle Scholar
  21. 21.
    Murphy MB, Kohner E, Lewis PJ et al (1982) Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up. Lancet II: 1293CrossRefGoogle Scholar
  22. 22.
    Amery A, Bulpitt C, Schaepdryver de A et al (1978) Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet I: 681CrossRefGoogle Scholar
  23. 23.
    Ames RP, Hill P (1976) Elevation of serum lipid levels during diuretic therapy of hypertension. Am J Med 61: 748PubMedCrossRefGoogle Scholar
  24. 24.
    Grimm RH, Leon AS, Hunningh ake DB et al (1981) Effects of thiazide diuretics on plasma li-pids and lipoproteins in mildly hypertensive patients. Ann Int Med 94: 7PubMedGoogle Scholar
  25. 25.
    Schnaper H, Fitz A, Fröhlich E et al (1977) Chlorthalidone and serum cholesterol. Lancet II: 295CrossRefGoogle Scholar
  26. 26.
    Glück Z, Baumgartner G, Weidmann P et al (1978) Increased ratio between serum ß- and α-li-poproteins during diuretic therapy: an adverse effect? Clin Sei Mol Med 55: 325sGoogle Scholar
  27. 27.
    Glück Z, Weidmann P, Mordasini R et al (1980) Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone. Metabolism 29: 240PubMedCrossRefGoogle Scholar
  28. 28.
    Valimäki M, Harno K und Nikkilä EA (1983) Serum lipoproteins and indices of glucose tolerance during diuretic therapy: a comparison between hydrochlorothiazide and piretanide. J Cardiovasc Pharmacol 5: 525PubMedCrossRefGoogle Scholar
  29. 29.
    Medical Research Council Working Party on Mild to Moderate Hypertension (1983) Ventricular extrasystoles during thiazide treatment: Substudy of MRC mild hypertension trial. Br Med J 287: 1249Google Scholar
  30. 30.
    Kaplan NM (1984) Our appropriate concern about hypokalemia. Am J Med 77: 1PubMedCrossRefGoogle Scholar
  31. 31.
    Ames RP (1983) Negative effects of diuretic drugs on metabolic risk factors for coronary heart disease: possible alternative drug therapies. Am J Cardiol 51: 632PubMedCrossRefGoogle Scholar
  32. 32.
    Berglund G, Sannerstedt R, Andersson O et al (1978) Coronary heart disease after treatment of hypertension. Lancet 1: 1PubMedCrossRefGoogle Scholar
  33. 33.
    Materson BJ, Oster JR, Michael UF et al (1978) Dose response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther 24: 192PubMedGoogle Scholar
  34. 34.
    Tweeddale MG, Ogilvie RI, Ruedy J (1977) Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther 22: 519PubMedGoogle Scholar
  35. 35.
    Lohmann FW (1981) Die Beeinflussung des Stoffwechsels durch Beta-Rezeptoren-Blocker. Klin Wochenschr 59: 49PubMedCrossRefGoogle Scholar
  36. 36.
    Beta-Blocker Heart Attack Trial Study Group (1981) The Beta-Blocker Heart Attack Trial. J Am Med Assoc, 246: 2073CrossRefGoogle Scholar
  37. 37.
    Norwegian Multicenter Study Group (1981) Timolol-induced reduction in mortality and rein- farction in patients surviving acute myocardial infarction. N Engl J Med 304: 801CrossRefGoogle Scholar
  38. 38.
    Spivack C, Ockens S und Frishman H (1983) Calcium antagonists. Clinical use in the treatment of systemic hypertension. Drugs, 25: 154PubMedCrossRefGoogle Scholar
  39. 39.
    The IPPPSH Collaborative Group (1985) Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker Oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertension 3: 379CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • A. Distler
    • 1
  1. 1.Medizinische Klinik und PoliklinikKlinikum Steglitz der Freien Universität BerlinBerlin 45Germany

Personalised recommendations